IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.632
AS - Asia 1.278
NA - Nord America 815
SA - Sud America 109
AF - Africa 30
OC - Oceania 4
Totale 9.868
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.391
US - Stati Uniti d'America 776
SG - Singapore 482
CN - Cina 354
VN - Vietnam 254
FR - Francia 72
BR - Brasile 66
HK - Hong Kong 65
DE - Germania 42
FI - Finlandia 40
JP - Giappone 25
AR - Argentina 18
CA - Canada 17
IN - India 15
BD - Bangladesh 14
GB - Regno Unito 13
MX - Messico 13
ES - Italia 10
ID - Indonesia 10
AT - Austria 9
NL - Olanda 9
PL - Polonia 9
IQ - Iraq 8
TR - Turchia 7
CH - Svizzera 6
EG - Egitto 6
IE - Irlanda 6
MY - Malesia 6
ZA - Sudafrica 6
CO - Colombia 5
EC - Ecuador 5
PH - Filippine 5
RU - Federazione Russa 5
AU - Australia 4
IL - Israele 4
PY - Paraguay 4
RO - Romania 4
UA - Ucraina 4
UY - Uruguay 4
AO - Angola 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
KR - Corea 3
LT - Lituania 3
MA - Marocco 3
PK - Pakistan 3
SA - Arabia Saudita 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
CY - Cipro 2
GT - Guatemala 2
HR - Croazia 2
KE - Kenya 2
OM - Oman 2
RS - Serbia 2
SE - Svezia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
ME - Montenegro 1
MU - Mauritius 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
SI - Slovenia 1
SR - Suriname 1
TH - Thailandia 1
ZM - Zambia 1
Totale 9.868
Salva come PNG Salva come JPEG
Città #
Genoa 3.920
Genova 1.898
Vado Ligure 890
Rapallo 512
San Jose 226
Ashburn 206
Singapore 202
Council Bluffs 88
Ho Chi Minh City 80
Lauterbourg 67
Beijing 59
Hong Kong 58
Hanoi 54
Milan 39
Helsinki 37
New York 30
St Louis 30
Frankfurt am Main 25
Bordighera 22
Tokyo 21
Santa Clara 18
Da Nang 14
Haiphong 12
Valenza 12
São Paulo 11
Naples 10
Mexico City 9
Amsterdam 8
Bologna 8
Rome 8
Can Tho 7
Orem 7
Tianjin 7
Dublin 6
Los Angeles 6
Vienna 6
City of London 5
Des Moines 5
Giessen 5
Goiânia 5
Istanbul 5
Turin 5
Warsaw 5
Zurich 5
Atlanta 4
Baghdad 4
Johannesburg 4
London 4
Modena 4
Montreal 4
New Delhi 4
Quận Ba 4
Suzhou 4
Thái Nguyên 4
Brugherio 3
Buenos Aires 3
Cairo 3
Chennai 3
Chicago 3
Denver 3
Hải Dương 3
Lappeenranta 3
Nuremberg 3
Quito 3
Quận Bình Thạnh 3
Rovereto 3
Sydney 3
Tel Aviv 3
Tunis 3
Verona 3
Algiers 2
Asunción 2
Baku 2
Bandung 2
Beinasco 2
Belgrade 2
Belo Horizonte 2
Berlin 2
Biên Hòa 2
Boston 2
Brantford 2
Buffalo 2
Busto Arsizio 2
Bình Phước 2
Bắc Giang 2
Bắc Ninh 2
Casablanca 2
Cleveland 2
Curitiba 2
Cyberjaya 2
Dhaka 2
Dimāpur 2
Florence 2
Guangzhou 2
Jakarta 2
Kyiv 2
Leipzig 2
Luanda 2
Madrid 2
Mendoza 2
Totale 8.801
Salva come PNG Salva come JPEG
Nome #
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 307
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 249
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 230
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 230
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 214
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 208
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 206
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 203
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 202
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 194
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 191
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 183
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 178
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 163
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 162
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 159
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 156
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 153
Current State of Target Treatment in BRAF Mutated Melanoma 152
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 150
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 150
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 149
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 143
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 142
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 142
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 141
Solar radiation as a risk factor for cutaneous melanoma: Review 138
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 135
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 131
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 129
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 127
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 122
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 114
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 114
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 113
How to make immunotherapy an effective therapeutic choice for uveal melanoma 108
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 105
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 105
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 105
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 101
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 98
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 96
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 95
Primary endobronchial melanoma: a case report and clinical management indications 94
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 89
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 88
Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: Surgical technique and preliminary results 86
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 83
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 79
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 76
Hedgehog Inhibitors beyond Clinical Complete Response in Basal Cell Carcinoma: Should i Stop or Should i Go? 75
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 75
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 73
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 71
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 71
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 70
Molecular Assessment in Patients with Melanoma: When and Why? 70
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 68
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors 65
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 65
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 64
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 63
How I perform fertility preservation in breast cancer patients 62
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 61
mAbs targeting CTLA-4 and clinical outcomes 59
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 59
Machine Learning Methods for Gene Selection in Uveal Melanoma 58
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 56
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 56
Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study 56
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 54
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 50
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 50
Current status and perspectives in immunotherapy for metastatic melanoma 48
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 48
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 47
Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab 45
Treatment of metastatic uveal melanoma with intravenous fotemustine 45
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 45
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 44
The adjuvant treatment revolution for high-risk melanoma patients 44
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 43
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study 43
Sun exposure and melanoma prognostic factors 42
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 41
No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study 41
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 40
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 39
Update on Metastatic Uveal Melanoma: Progress and Challenges 39
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review 39
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program 38
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 37
Binimetinib for the treatment of NRAS-mutant melanoma 37
Uveal melanoma 36
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 34
Uveal melanoma 33
Immune-related osteitis mimicking femoral head osteonecrosis during dual checkpoint blockade: a case report 33
Management of immune-related adverse events during treatment with immune checkpoint inhibitors 33
Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib 32
Upcoming strategies for the treatment of metastatic melanoma 30
Totale 9.815
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.229
article - articoli 33.630
book - libri 0
conference - conferenze 275
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 774
Totale 69.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021100 0 0 0 0 0 0 0 0 0 48 35 17
2021/2022434 21 21 23 46 21 42 19 81 38 61 13 48
2022/2023620 49 52 6 53 112 93 4 48 89 8 98 8
2023/2024598 12 42 18 81 34 80 21 56 30 29 36 159
2024/20252.569 102 167 51 137 297 247 196 375 103 105 252 537
2025/20264.359 503 194 659 458 518 290 606 256 423 452 0 0
Totale 10.151